Day: February 28, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2021 financial results. “In 2021 strong execution drove significant advancement of our pipeline. The achievement of strategic milestones and positive data further de-risked our ongoing and potential future clinical programs,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. “We are building on this momentum in 2022 with significant data readouts anticipated in our lead programs of idiopathic pulmonary fibrosis and primary sclerosing cholangitis, as well as planned investigational...

Demonstrated tangible market progress and shipped 17 instruments through year end 2021 REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2021. “This has been a momentous year for Seer, one that paved the way for our technology in the hands of lighthouse collaborators and customers, demonstrated the unique benefits of our technology, and positioned Seer to open up new possibilities for researchers with an unbiased, scalable approach to proteomics,” said Omid Farokhzad, Chief Executive Officer and Chair, “As we enter 2022, we are excited about our market opportunity, confident in what the Proteograph Product Suite can deliver and...

Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020 SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early October 2022 Completed acquisition of Adamas Pharmaceuticals, Inc. in November 2021; integration well underway Qelbree® continued its growth trajectory, closing the year with 13,380 prescriptions in December 2021ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced preliminary financial results for the fourth quarter and full year of 2021, and associated Company developments. Net Product Sales For full year 2021, preliminary net product...

Year-end number of customers contributing more than $100,000 in trailing 12 months revenue up approximately 66% year over year Fourth quarter total revenue of $1,071.4 million, up 21% year over year; full fiscal year total revenue of $4,099.9 million, up 55% year over year Fourth quarter GAAP income from operations of $251.8 million, down 2% year over year; full fiscal year GAAP income from operations of $1,063.6 million, up 61% year over year Fourth quarter non-GAAP income from operations of $420.3 million, up 16% year over year; full fiscal year non-GAAP income from operations of $1,657.1 million, up 69% year over year Authorization to repurchase up to $1.0 billion of Zoom’s Class A common stockSAN JOSE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), a leading provider of video-first...

Delivered record Q4 2021 revenue of $75.6 million, representing 34% growth, GAAP net income margin of 37% and adjusted EBITDA margin of 51%Full year record revenue of $226.9 million, representing 53% growth, GAAP net income margin of 25% and adjusted EBITDA margin of 42% NO-HEADQUARTERS/REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. “For the second consecutive year, we delivered an incredible combination of revenue growth and profitability. Organic revenue growth in 2021 was 53% over last year, reflecting significant market share gains in a large and rapidly growing market,” said Rajeev Goel, co-founder...

2021 Revenues up 19% with 19% EBITDA Margin BOULDER, Colo., Feb. 28, 2022 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the fourth quarter and full year ended December 31, 2021. HighlightsGenerated positive operating income for the first full year since the launch of Gaia’s streaming business 19% revenue growth in 2021, ending the year with 821,000 members Sixth consecutive quarter of positive earnings and double-digit revenue growth“Our first year with annual operating income represents an important milestone for Gaia,” said Jirka Rysavy, Gaia’s Chairman and CEO. “We are now in position to expand more aggressively internationally, leveraging our existing operating infrastructure and worldwide rights to virtually all of our content library.” A summary of...

Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2 combination clinical trial of bemnifosbuvir and ruzasvir (RZR) as potential best-in-class pan genotypic regimen for hepatitis C virus (HCV) in 2H 2022 Advancing AT-752 as a potential first antiviral treatment for dengue fever in Phase 2 program in 1H 2022 Conference call at 4:30 p.m. ET today BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.    “During 2022, we expect to make meaningful progress advancing three Phase 2 programs...